These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 21737488)

  • 1. Clusterin inhibition using OGX-011 synergistically enhances Hsp90 inhibitor activity by suppressing the heat shock response in castrate-resistant prostate cancer.
    Lamoureux F; Thomas C; Yin MJ; Kuruma H; Beraldi E; Fazli L; Zoubeidi A; Gleave ME
    Cancer Res; 2011 Sep; 71(17):5838-49. PubMed ID: 21737488
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Suppression of heat shock protein 27 using OGX-427 induces endoplasmic reticulum stress and potentiates heat shock protein 90 inhibitors to delay castrate-resistant prostate cancer.
    Lamoureux F; Thomas C; Yin MJ; Fazli L; Zoubeidi A; Gleave ME
    Eur Urol; 2014 Jul; 66(1):145-55. PubMed ID: 24411988
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clusterin inhibition using OGX-011 synergistically enhances zoledronic acid activity in osteosarcoma.
    Lamoureux F; Baud'huin M; Ory B; Guiho R; Zoubeidi A; Gleave M; Heymann D; Rédini F
    Oncotarget; 2014 Sep; 5(17):7805-19. PubMed ID: 25138053
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cotargeting Androgen Receptor and Clusterin Delays Castrate-Resistant Prostate Cancer Progression by Inhibiting Adaptive Stress Response and AR Stability.
    Matsumoto H; Yamamoto Y; Shiota M; Kuruma H; Beraldi E; Matsuyama H; Zoubeidi A; Gleave M
    Cancer Res; 2013 Aug; 73(16):5206-17. PubMed ID: 23786771
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hsp90 inhibitor 17-AAG inhibits progression of LuCaP35 xenograft prostate tumors to castration resistance.
    O'Malley KJ; Langmann G; Ai J; Ramos-Garcia R; Vessella RL; Wang Z
    Prostate; 2012 Jul; 72(10):1117-23. PubMed ID: 22161776
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel HSP90 inhibitor delays castrate-resistant prostate cancer without altering serum PSA levels and inhibits osteoclastogenesis.
    Lamoureux F; Thomas C; Yin MJ; Kuruma H; Fazli L; Gleave ME; Zoubeidi A
    Clin Cancer Res; 2011 Apr; 17(8):2301-13. PubMed ID: 21349995
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 17-ABAG, a novel geldanamycin derivative, inhibits LNCaP-cell proliferation through heat shock protein 90 inhibition.
    Lin Z; Peng R; Li Z; Wang Y; Lu C; Shen Y; Wang J; Shi G
    Int J Mol Med; 2015 Aug; 36(2):424-32. PubMed ID: 26059743
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting GRP75 improves HSP90 inhibitor efficacy by enhancing p53-mediated apoptosis in hepatocellular carcinoma.
    Guo W; Yan L; Yang L; Liu X; E Q; Gao P; Ye X; Liu W; Zuo J
    PLoS One; 2014; 9(1):e85766. PubMed ID: 24465691
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-throughput screens identify HSP90 inhibitors as potent therapeutics that target inter-related growth and survival pathways in advanced prostate cancer.
    Jansson KH; Tucker JB; Stahl LE; Simmons JK; Fuller C; Beshiri ML; Agarwal S; Fang L; Hynes PG; Alilin AN; Lake R; Abbey YC; Cawley J; Tice CM; Yin J; McKnight C; Klummp-Thomas C; Zhang X; Guha R; Hoover S; Simpson RM; Nguyen HM; Corey E; Thomas CJ; Proia DA; Kelly K
    Sci Rep; 2018 Nov; 8(1):17239. PubMed ID: 30467317
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cisplatin abrogates the geldanamycin-induced heat shock response.
    McCollum AK; Lukasiewicz KB; Teneyck CJ; Lingle WL; Toft DO; Erlichman C
    Mol Cancer Ther; 2008 Oct; 7(10):3256-64. PubMed ID: 18852129
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Novel Class of Hsp90 C-Terminal Modulators Have Pre-Clinical Efficacy in Prostate Tumor Cells Without Induction of a Heat Shock Response.
    Armstrong HK; Koay YC; Irani S; Das R; Nassar ZD; ; Selth LA; Centenera MM; McAlpine SR; Butler LM
    Prostate; 2016 Dec; 76(16):1546-1559. PubMed ID: 27526951
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of constitutive and cxc-chemokine-induced NF-kappaB activity potentiates ansamycin-based HSP90-inhibitor cytotoxicity in castrate-resistant prostate cancer cells.
    Seaton A; Maxwell PJ; Hill A; Gallagher R; Pettigrew J; Wilson RH; Waugh DJ
    Br J Cancer; 2009 Nov; 101(9):1620-9. PubMed ID: 19809428
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heteronemin, a Marine Sesterterpenoid-Type Metabolite, Induces Apoptosis in Prostate LNcap Cells via Oxidative and ER Stress Combined with the Inhibition of Topoisomerase II and Hsp90.
    Lee MG; Liu YC; Lee YL; El-Shazly M; Lai KH; Shih SP; Ke SC; Hong MC; Du YC; Yang JC; Sung PJ; Wen ZH; Lu MC
    Mar Drugs; 2018 Jun; 16(6):. PubMed ID: 29890785
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Targeting Clusterin Using OGX-011 on Antitumor Activity of Temsirolimus in a Human Renal Cell Carcinoma Model.
    Nishikawa M; Miyake H; Gleave M; Fujisawa M
    Target Oncol; 2017 Feb; 12(1):69-79. PubMed ID: 27526062
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination of rapamycin, CI-1040, and 17-AAG inhibits metastatic capacity of prostate cancer via Slug inhibition.
    Ding G; Feng C; Jiang H; Ding Q; Zhang L; Na R; Xu H; Liu J
    PLoS One; 2013; 8(10):e77400. PubMed ID: 24130883
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clusterin inhibition using OGX-011 synergistically enhances antitumour activity of sorafenib in a human renal cell carcinoma model.
    Kususda Y; Miyake H; Gleave ME; Fujisawa M
    Br J Cancer; 2012 Jun; 106(12):1945-52. PubMed ID: 22588555
    [TBL] [Abstract][Full Text] [Related]  

  • 17. siRNA Lipid Nanoparticle Potently Silences Clusterin and Delays Progression When Combined with Androgen Receptor Cotargeting in Enzalutamide-Resistant Prostate Cancer.
    Yamamoto Y; Lin PJ; Beraldi E; Zhang F; Kawai Y; Leong J; Katsumi H; Fazli L; Fraser R; Cullis PR; Gleave M
    Clin Cancer Res; 2015 Nov; 21(21):4845-55. PubMed ID: 26106075
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potent activity of the Hsp90 inhibitor ganetespib in prostate cancer cells irrespective of androgen receptor status or variant receptor expression.
    He S; Zhang C; Shafi AA; Sequeira M; Acquaviva J; Friedland JC; Sang J; Smith DL; Weigel NL; Wada Y; Proia DA
    Int J Oncol; 2013 Jan; 42(1):35-43. PubMed ID: 23152004
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clusterin facilitates stress-induced lipidation of LC3 and autophagosome biogenesis to enhance cancer cell survival.
    Zhang F; Kumano M; Beraldi E; Fazli L; Du C; Moore S; Sorensen P; Zoubeidi A; Gleave ME
    Nat Commun; 2014 Dec; 5():5775. PubMed ID: 25503391
    [TBL] [Abstract][Full Text] [Related]  

  • 20. P-Glycoprotein-mediated resistance to Hsp90-directed therapy is eclipsed by the heat shock response.
    McCollum AK; TenEyck CJ; Stensgard B; Morlan BW; Ballman KV; Jenkins RB; Toft DO; Erlichman C
    Cancer Res; 2008 Sep; 68(18):7419-27. PubMed ID: 18794130
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.